CGN Nuclear Technology Development Co., Ltd.(000881.SZ)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 6,652 | 7,999 | 6,945 | 6,353 | 6,168 | 5,553 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 271 | 177 | 200 | -737 | -362 | -287 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
CGN Nuclear Technology Development Co., Ltd. manufactures and sells cable materials and industrial electron accelerators in China. It provides ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, and industrial flaw detection accelerators. The company is also involved in the provision of electron beam treatment of specialty waste; antibiotic residue treatment technology; pharmaceutical wastewater treatment technology; medical sewage and solid waste disposal; park sewage treatment; printing and dyeing wastewater treatment technology; coal chemical coking wastewater treatment technology; chemical wastewater treatment technology; domestic sewage treatment technology; and hazardous waste concentrate treatment services. In addition, it provides new energy, irradiated, elastomer, and synthetic materials; modified polycarbonate and polyester, modified polypropylene, continuous fiber reinforced thermoplastic composites, and melt blown and radiation resistant polypropylene; and proton therapy tumor system equipment, raw materials and parts, radioactive medical isotopes, and hospital and nuclear drug products. Further, the company engages in production and sale of plastic; and real estate development, as well as contracting, irradiation processing, ocean shipping, maritime cargo transportation, ship investment and chartering, fishery, and project construction businesses. The company was formerly known as China Dalian International Cooperation (Group) Holdings Ltd. and changed its name to CGN Nuclear Technology Development Co., Ltd. in February 2017. CGN Nuclear Technology Development Co., Ltd. was founded in 1993 and is based in Shenzhen, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CGN Nuclear Technology Development Co., Ltd. (000881.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
CGN Nuclear Technology Development Co., Ltd. manufactures and sells cable materials and industrial electron accelerators in China. It provides ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, and industrial flaw detection accelerators. The company is also involved in the provision of electron beam treatment of specialty waste; antibiotic residue treatment technology; pharmaceutical wastewater treatment technology; medical sewage and solid waste disposal; park sewage treatment; printing and dyeing wastewater treatment technology; coal chemical coking wastewater treatment technology; chemical wastewater treatment technology; domestic sewage treatment technology; and hazardous waste concentrate treatment services. In addition, it provides new energy, irradiated, elastomer, and synthetic materials; modified polycarbonate and polyester, modified polypropylene, continuous fiber reinforced thermoplastic composites, and melt blown and radiation resistant polypropylene; and proton therapy tumor system equipment, raw materials and parts, radioactive medical isotopes, and hospital and nuclear drug products. Further, the company engages in production and sale of plastic; and real estate development, as well as contracting, irradiation processing, ocean shipping, maritime cargo transportation, ship investment and chartering, fishery, and project construction businesses. The company was formerly known as China Dalian International Cooperation (Group) Holdings Ltd. and changed its name to CGN Nuclear Technology Development Co., Ltd. in February 2017. CGN Nuclear Technology Development Co., Ltd. was founded in 1993 and is based in Shenzhen, China.